GlassScriptPhysician profile
Rubinder Singh Dab
NPI 1467430728
$4,110.50
in general payments reported to CMS, 2019-2025
38 companies · $702 in 2025
The $702 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $136 · 2021: $384 · 2022: $661 · 2023: $1,108 · 2024: $925 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,694 · Education: $42.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,693.54 |
| Education | $42.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $702.96 | 2019-2025 | |
| Abbott Laboratories | $394.64 | 2019-2025 | Cardiomems, Confirm Rx, Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $322.99 | 2020-2025 | Farxiga, Brilinta, Wainua |
| Pfizer INC. | $311.39 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $267.17 | 2019-2024 | Camzyos, Eliquis |
| Boston Scientific Corporation | $238.29 | 2022-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $192.35 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $174.62 | 2022-2025 | Repatha, Repatha |
| Heartflow, INC. | $162.57 | 2023-2025 | Ffrct |
| Janssen Pharmaceuticals, INC | $143.86 | 2022-2023 | Xarelto |
| Novo Nordisk INC | $134.65 | 2023-2025 | Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $132.92 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $126.51 | 2022-2024 | Onpattro |
| Scpharmaceuticals INC. | $98.75 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $86.53 | 2024 | Arcalyst |
Show all 36 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubinder Dab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.